Profile - To The Moon

VoN

Posts · 4Posts · 4
Following · 0Following · 0
Followers · 0Followers · 0

- VoNVoN
  ·2021-08-04
  Wow!
  Pfizer hikes 2021 outlook after vaccine boosts sales, profit
  Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter
  Pfizer hikes 2021 outlook after vaccine boosts sales, profit
  178 Comment
  1
  Share
  Report
- VoNVoN
  ·2021-07-31
  Hmmmm...
  Sorry, this post has been deleted
  255 Comment
  Like
  Share
  Report
- VoNVoN
  ·2021-07-31
  ??
  Nio, XPeng, Li Shares Rise, as China EV Stocks Rebound
  NIO, Li Auto and Xpeng continued the recovery from their July 21-27 drop Friday, even as other U.S.-
  Nio, XPeng, Li Shares Rise, as China EV Stocks Rebound
  129 Comment
  2
  Share
  Report
- VoNVoN
  ·2021-07-28
  Oohh..
  India Court Says Twitter in ‘Total Non Compliance’ of New Rules
  Twitter says it is setting up a new liaison office in India Court gives Twitter a week to show clear
  India Court Says Twitter in ‘Total Non Compliance’ of New Rules
  167 1
  2
  Share
  Report
No following yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4090466680926910","uuid":"4090466680926910","gmtCreate":1627363722783,"gmtModify":1627363722783,"name":"VoN","pinyin":"von","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":47,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":807796102,"gmtCreate":1628055606706,"gmtModify":1703500392534,"author":{"id":"4090466680926910","authorId":"4090466680926910","name":"VoN","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090466680926910","authorIdStr":"4090466680926910"},"themes":[],"htmlText":"Wow!&nbsp;","listText":"Wow!&nbsp;","text":"Wow!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807796102","repostId":"1156524625","repostType":4,"repost":{"id":"1156524625","pubTimestamp":1628053893,"share":"https://ttm.financial/m/news/1156524625?lang=&edition=fundamental","pubTime":"2021-08-04 13:11","market":"us","language":"en","title":"Pfizer hikes 2021 outlook after vaccine boosts sales, profit","url":"https://stock-news.laohu8.com/highlight/detail?id=1156524625","media":"Business Hala","summary":"Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter ","content":"<p>Strong sales of its COVID-19 vaccine and other drugs helped<b> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.</p>\n<p></p>\n<p>Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit to 59%, beating Wall Street’s expectations and helping the drug giant look forward to 2021. Helped to rapidly increase sales and profit forecasts.</p>\n<p>Amid the growing coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, generating nearly half of its revenue — $7.84 billion from direct sales and revenue splitting with its partner, Germany’s BioNTech.</p>\n<p>Pfizer now forecasts revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it has been contracted to provide by the end of the year. This does not include the contract signed last week to provide an additional 200 million doses to the US</p>\n<p>The New York company revealed on Wednesday that an ongoing trial of a booster shot given six months after the second vaccine dose showed that it increased antibody levels against the more-transmissible delta variant to 11 times higher in older people and younger people. increased more than five times. , compared to levels after two doses. The company also released data showing that six months after vaccination, the shots were 97% effective at preventing serious disease.</p>\n<p>“We are absolutely convinced that a booster will be needed,” CEO Albert Boerla said in an interview, “that a third dose of the original vaccine may be sufficient.” Still, in August Pfizer will begin testing a booster targeting the Delta version in volunteers, because “there’s so much at stake, you can’t take the risk.”</p>\n<p>Bourla said Pfizer has delivered more than 1 billion doses of the vaccine globally and expects to make 3 billion doses this year, with many more going to low- and middle-income countries. So far, most of the doses of all COVID-19 vaccines produced in Europe and the US have gone to rich countries.</p>\n<p>By the end of September, trials in 5- to 11-year-old volunteers should produce the safety and efficacy data necessary to obtain emergency use authorization in that age group, and data on trials in children 6 months to 5 years of age should be used. must comply. Soon according to Pfizer.</p>\n<p>The US Food and Drug Administration is now reviewing data that could lead to full approval of the vaccine for adults, which Borla said could reduce hesitation from vaccination.</p>\n<p>Second-quarter net income was $5.56 billion, or 98 cents per share, up from $3.49 billion, or 62 cents per share.</p>\n<p>Adjusted earnings, excluding one-time gains and losses, amounted to $6.08 billion, or $1.07 per share, significantly higher than Wall Street’s 97 cents.</p>\n<p>Its quarterly revenue of $18.98 billion is up from last year’s $9.86 billion, and also topped estimates.</p>\n<p>Pfizer shares rose $1.46, or 3.5%, to $43.56, near a 52-week high.</p>\n<p>Sales of Pfizer’s drugs for cancer and rare diseases, as well as drugs primarily used in hospitals, grew double-digit. Sales of Eliquis for preventing blood clots and stroke rose 16% to $1.48 billion, while Ibrance’s sales rose 4% to $1.4 billion in the quarter.</p>\n<p>Pfizer’s pneumonia vaccine Prevnar 13 – the world’s most lucrative vaccine by far – climbed 11% in sales to $1.24 billion amid the pandemic. The company won US approval in June for Prevnar 20, an updated version for adults that protects against seven more strains of pneumococcal disease.</p>\n<p>In May, Pfizer and partner Myovent received approval for MyFembry to reduce heavy menstrual bleeding due to uterine fibroids in premenopausal women.</p>\n<p>Pfizer’s head of research Mikel Dolstein outlined eight major research programs with the potential to have a major impact on public health, including a pill to treat COVID-19 and vaccines against Lyme disease and respiratory syncytial virus, which occur each year. Infects and kills more than 5% of adults. about 15,000 of them in the US</p>\n<p>Pfizer now expects adjusted full-year earnings in the range of $3.95 to $4.05 per share, up from its May forecast of $3.55 to $3.65 per share, and revenue in the range of $78 billion to $80 billion. , from $70.5 billion to $72.5 billion.</p>\n<p></p>","source":"lsy1627951004805","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer hikes 2021 outlook after vaccine boosts sales, profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer hikes 2021 outlook after vaccine boosts sales, profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 13:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/><strong>Business Hala</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.\n\nStrong sales of its COVID-...</p>\n\n<a href=\"https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156524625","content_text":"Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.\n\nStrong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit to 59%, beating Wall Street’s expectations and helping the drug giant look forward to 2021. Helped to rapidly increase sales and profit forecasts.\nAmid the growing coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, generating nearly half of its revenue — $7.84 billion from direct sales and revenue splitting with its partner, Germany’s BioNTech.\nPfizer now forecasts revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it has been contracted to provide by the end of the year. This does not include the contract signed last week to provide an additional 200 million doses to the US\nThe New York company revealed on Wednesday that an ongoing trial of a booster shot given six months after the second vaccine dose showed that it increased antibody levels against the more-transmissible delta variant to 11 times higher in older people and younger people. increased more than five times. , compared to levels after two doses. The company also released data showing that six months after vaccination, the shots were 97% effective at preventing serious disease.\n“We are absolutely convinced that a booster will be needed,” CEO Albert Boerla said in an interview, “that a third dose of the original vaccine may be sufficient.” Still, in August Pfizer will begin testing a booster targeting the Delta version in volunteers, because “there’s so much at stake, you can’t take the risk.”\nBourla said Pfizer has delivered more than 1 billion doses of the vaccine globally and expects to make 3 billion doses this year, with many more going to low- and middle-income countries. So far, most of the doses of all COVID-19 vaccines produced in Europe and the US have gone to rich countries.\nBy the end of September, trials in 5- to 11-year-old volunteers should produce the safety and efficacy data necessary to obtain emergency use authorization in that age group, and data on trials in children 6 months to 5 years of age should be used. must comply. Soon according to Pfizer.\nThe US Food and Drug Administration is now reviewing data that could lead to full approval of the vaccine for adults, which Borla said could reduce hesitation from vaccination.\nSecond-quarter net income was $5.56 billion, or 98 cents per share, up from $3.49 billion, or 62 cents per share.\nAdjusted earnings, excluding one-time gains and losses, amounted to $6.08 billion, or $1.07 per share, significantly higher than Wall Street’s 97 cents.\nIts quarterly revenue of $18.98 billion is up from last year’s $9.86 billion, and also topped estimates.\nPfizer shares rose $1.46, or 3.5%, to $43.56, near a 52-week high.\nSales of Pfizer’s drugs for cancer and rare diseases, as well as drugs primarily used in hospitals, grew double-digit. Sales of Eliquis for preventing blood clots and stroke rose 16% to $1.48 billion, while Ibrance’s sales rose 4% to $1.4 billion in the quarter.\nPfizer’s pneumonia vaccine Prevnar 13 – the world’s most lucrative vaccine by far – climbed 11% in sales to $1.24 billion amid the pandemic. The company won US approval in June for Prevnar 20, an updated version for adults that protects against seven more strains of pneumococcal disease.\nIn May, Pfizer and partner Myovent received approval for MyFembry to reduce heavy menstrual bleeding due to uterine fibroids in premenopausal women.\nPfizer’s head of research Mikel Dolstein outlined eight major research programs with the potential to have a major impact on public health, including a pill to treat COVID-19 and vaccines against Lyme disease and respiratory syncytial virus, which occur each year. Infects and kills more than 5% of adults. about 15,000 of them in the US\nPfizer now expects adjusted full-year earnings in the range of $3.95 to $4.05 per share, up from its May forecast of $3.55 to $3.65 per share, and revenue in the range of $78 billion to $80 billion. , from $70.5 billion to $72.5 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802997032,"gmtCreate":1627704396726,"gmtModify":1703495014587,"author":{"id":"4090466680926910","authorId":"4090466680926910","name":"VoN","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090466680926910","authorIdStr":"4090466680926910"},"themes":[],"htmlText":"Hmmmm...&nbsp;","listText":"Hmmmm...&nbsp;","text":"Hmmmm...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/802997032","repostId":"1172839147","repostType":4,"isVote":1,"tweetType":1,"viewCount":255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802994348,"gmtCreate":1627704350184,"gmtModify":1703495014103,"author":{"id":"4090466680926910","authorId":"4090466680926910","name":"VoN","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090466680926910","authorIdStr":"4090466680926910"},"themes":[],"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/802994348","repostId":"1137888611","repostType":4,"repost":{"id":"1137888611","pubTimestamp":1627688479,"share":"https://ttm.financial/m/news/1137888611?lang=&edition=fundamental","pubTime":"2021-07-31 07:41","market":"us","language":"en","title":"Nio, XPeng, Li Shares Rise, as China EV Stocks Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1137888611","media":"The Street","summary":"NIO, Li Auto and Xpeng continued the recovery from their July 21-27 drop Friday, even as other U.S.-","content":"<blockquote>\n NIO, Li Auto and Xpeng continued the recovery from their July 21-27 drop Friday, even as other U.S.-listed China stocks fell.\n</blockquote>\n<p>Chinese electric vehicle stocks, including NIO&nbsp;(<b>NIO</b>) , Li Auto&nbsp;(<b>LI</b>) and Xpeng&nbsp;(<b>XPEV</b>) , continued the rebound from their July 21-27 drop Friday, even as other U.S.-listed China stocks fell.</p>\n<p>Nio gained 4% to $44.50, Li 11% to $33.97 and Xpeng 9% to $41.38. Meanwhile, Alibaba BABA slid 2% to $195.19 and Didi DIDI 3% to $9.57.</p>\n<p>Fear of stringent Chinese regulation is depressing non-EV stocks. But China hasn’t made much noise about cracking down on EV makers. It’s an industry the government would like to dominate.</p>\n<p>So it may have no desire to put the hammer down on EV companies, and that’s likely buttressing their shares Friday.</p>\n<p>When it comes to U.S. EV stocks, Tesla&nbsp;(<b>TSLA</b>) -Get Report&nbsp;is the big daddy, of course. Its shares are up 5% to $677.75 Friday, leaving them up 8% for the past five days.</p>\n<p>The companyposted stronger-than-expected earningsfor the second quarter Monday and said it's on track to build the first Model Y sedans from new facilities in Austin and Berlin before year-end.</p>\n<p>Chief Executive Elon Musk, however, added in an investor call following the earnings report that the global shortage in semiconductor supplies remains \"quite serious\" and could impact production rates over the second half of the year.</p>\n<p>Volume growth will depend on the availability of other parts in the global supply chain, he said.</p>\n<p>Musk also said he would no longer participate in regular earnings calls, unless he had \"something really important to say\".</p>\n<p>Tesla said adjusted profit for the latest quarter was $1.45 per share, creaming analysts’ consensus forecast of 98 cents.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio, XPeng, Li Shares Rise, as China EV Stocks Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio, XPeng, Li Shares Rise, as China EV Stocks Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-31 07:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/china-ev-stocks-rebound-nio-xpeng-li><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NIO, Li Auto and Xpeng continued the recovery from their July 21-27 drop Friday, even as other U.S.-listed China stocks fell.\n\nChinese electric vehicle stocks, including NIO (NIO) , Li Auto (LI) and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/china-ev-stocks-rebound-nio-xpeng-li\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LI":"理想汽车","XPEV":"小鹏汽车","NIO":"蔚来"},"source_url":"https://www.thestreet.com/investing/china-ev-stocks-rebound-nio-xpeng-li","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137888611","content_text":"NIO, Li Auto and Xpeng continued the recovery from their July 21-27 drop Friday, even as other U.S.-listed China stocks fell.\n\nChinese electric vehicle stocks, including NIO (NIO) , Li Auto (LI) and Xpeng (XPEV) , continued the rebound from their July 21-27 drop Friday, even as other U.S.-listed China stocks fell.\nNio gained 4% to $44.50, Li 11% to $33.97 and Xpeng 9% to $41.38. Meanwhile, Alibaba BABA slid 2% to $195.19 and Didi DIDI 3% to $9.57.\nFear of stringent Chinese regulation is depressing non-EV stocks. But China hasn’t made much noise about cracking down on EV makers. It’s an industry the government would like to dominate.\nSo it may have no desire to put the hammer down on EV companies, and that’s likely buttressing their shares Friday.\nWhen it comes to U.S. EV stocks, Tesla (TSLA) -Get Report is the big daddy, of course. Its shares are up 5% to $677.75 Friday, leaving them up 8% for the past five days.\nThe companyposted stronger-than-expected earningsfor the second quarter Monday and said it's on track to build the first Model Y sedans from new facilities in Austin and Berlin before year-end.\nChief Executive Elon Musk, however, added in an investor call following the earnings report that the global shortage in semiconductor supplies remains \"quite serious\" and could impact production rates over the second half of the year.\nVolume growth will depend on the availability of other parts in the global supply chain, he said.\nMusk also said he would no longer participate in regular earnings calls, unless he had \"something really important to say\".\nTesla said adjusted profit for the latest quarter was $1.45 per share, creaming analysts’ consensus forecast of 98 cents.","news_type":1},"isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801064054,"gmtCreate":1627474525378,"gmtModify":1703490631498,"author":{"id":"4090466680926910","authorId":"4090466680926910","name":"VoN","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090466680926910","authorIdStr":"4090466680926910"},"themes":[],"htmlText":"Oohh..&nbsp;","listText":"Oohh..&nbsp;","text":"Oohh..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/801064054","repostId":"1138748740","repostType":4,"repost":{"id":"1138748740","pubTimestamp":1627471461,"share":"https://ttm.financial/m/news/1138748740?lang=&edition=fundamental","pubTime":"2021-07-28 19:24","market":"us","language":"en","title":"India Court Says Twitter in ‘Total Non Compliance’ of New Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=1138748740","media":"Bloomberg","summary":"Twitter says it is setting up a new liaison office in India\nCourt gives Twitter a week to show clear","content":"<ul>\n <li>Twitter says it is setting up a new liaison office in India</li>\n <li>Court gives Twitter a week to show clear steps for compliance</li>\n</ul>\n<p>An Indian court said statements by&nbsp;Twitter Inc.“clearly show total non-compliance” with the country’s new information technology rules, a development that can potentially escalate the ongoing tensions between the social media giant and the Indian government.</p>\n<p>The high court in Delhi gave the social media giant a week to respond on how it intends to comply. “I am giving you a long rope but please don’t expect this to go on and on,” Justice Rekha Palli said during the hearing.</p>\n<p>The new rules require online companies in India to make stricter disclosures, with the large social media companies to appoint dedicated officers for redressing grievance against content and compliance.</p>\n<p>Facebook Inc’s WhatsApp has already challenged the new rules that also demand messaging apps reveal to authorities information about encrypted messages. Non compliance of rules can result in losing legal immunity from prosecution for content posted by users on social platforms.</p>\n<p>During the hearing the judge said the affidavits, or statements under oath, submitted by Twitter and its official were “unacceptable” as the company had appointed an employee through a third party contractor as its compliance and grievance officer, instead of a senior person in the company as required by the rules.</p>\n<p>Twitter’s lawyer Sajan Poovayya told the court that the company was in the process to comply with the rules and is also setting up a liaison office in India. He said the company will submit a new statement before the hearing next week.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>India Court Says Twitter in ‘Total Non Compliance’ of New Rules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndia Court Says Twitter in ‘Total Non Compliance’ of New Rules\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 19:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-07-28/india-court-says-twitter-in-total-non-compliance-of-new-rules?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Twitter says it is setting up a new liaison office in India\nCourt gives Twitter a week to show clear steps for compliance\n\nAn Indian court said statements by Twitter Inc.“clearly show total non-...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-07-28/india-court-says-twitter-in-total-non-compliance-of-new-rules?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWTR":"Twitter"},"source_url":"https://www.bloomberg.com/news/articles/2021-07-28/india-court-says-twitter-in-total-non-compliance-of-new-rules?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138748740","content_text":"Twitter says it is setting up a new liaison office in India\nCourt gives Twitter a week to show clear steps for compliance\n\nAn Indian court said statements by Twitter Inc.“clearly show total non-compliance” with the country’s new information technology rules, a development that can potentially escalate the ongoing tensions between the social media giant and the Indian government.\nThe high court in Delhi gave the social media giant a week to respond on how it intends to comply. “I am giving you a long rope but please don’t expect this to go on and on,” Justice Rekha Palli said during the hearing.\nThe new rules require online companies in India to make stricter disclosures, with the large social media companies to appoint dedicated officers for redressing grievance against content and compliance.\nFacebook Inc’s WhatsApp has already challenged the new rules that also demand messaging apps reveal to authorities information about encrypted messages. Non compliance of rules can result in losing legal immunity from prosecution for content posted by users on social platforms.\nDuring the hearing the judge said the affidavits, or statements under oath, submitted by Twitter and its official were “unacceptable” as the company had appointed an employee through a third party contractor as its compliance and grievance officer, instead of a senior person in the company as required by the rules.\nTwitter’s lawyer Sajan Poovayya told the court that the company was in the process to comply with the rules and is also setting up a liaison office in India. He said the company will submit a new statement before the hearing next week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}